MARATTO

article · Pharmaceuticals

Exploring the Multifaceted Phytochemical Profile of Nigella sativa and the Therapeutic Potential of Thymoquinone

2026Open accessCairo University

Abstract

<b>Background:</b><i>Nigella sativa</i> (black cumin) seeds are renowned for their ethnomedicinal significance and are rich in bioactive phytochemicals, which contribute to food preservation and the prevention of various diseases through their antimicrobial and antioxidant properties. Accordingly, this study aimed to characterize the phytochemical composition of <i>N. sativa</i> seed extracts, isolate thymoquinone, and assess their antibacterial, antibiofilm, antioxidant, anti-inflammatory and antidiabetic activities. <b>Methods:</b><i>Nigella sativa</i> seed extracts were prepared using solvents of increasing polarity and analyzed for phytochemical content. Metabolite profiling was performed using UHPLC/QTOF-MS. Thymoquinone, the major constituent, was isolated via thin-layer chromatography (TLC), further purified using semi-preparative reverse-phase high-performance liquid chromatography (RP-HPLC), and evaluated in vitro for antibacterial, antibiofilm, antioxidant, anti-inflammatory, and antidiabetic activities. <b>Results:</b> Extraction yields ranged from 5.5% to 8.4% (<i>w</i>/<i>w</i>), with methanol yielding the highest phenol (6.34 ± 0.31 mg GAE/mL) and flavonoid (5.12 ± 0.26 mg QE/mL) contents. UHPLC/QTOF-MS revealed a chemically diverse profile dominated by thymoquinone (58% relative abundance), alongside <i>p</i>-cymene, carvacrol, longifolene, and nigellidine. Thymoquinone (Rf = 0.56) was initially isolated from the methanolic extract with a yield of 270 mg/g and further purified from preparative TLC fractions using semi-preparative RP-HPLC, affording 82 mg of >95% pure compound with a 68.3% recovery, suitable for subsequent biological assays. It inhibited Gram-positive and Gram-negative bacteria, with MICs of 62.5 µg/mL against <i>Staphylococcus aureus</i>, <i>Bacillus subtilis</i>, and <i>Listeria monocytogenes</i>; 125-250 µg/mL against <i>Escherichia coli</i> and <i>Salmonella typhimurium</i>; and 500 µg/mL against <i>Pseudomonas aeruginosa</i>. Thymoquinone reduced biofilm formation (>80% at 25-50 µg/mL; MBIC<sub>50</sub> ≈ 5.4-11.6 µg/mL), exhibited antioxidant activity (DPPH IC<sub>50</sub> = 52.3 ± 2. 1 µg/mL; ABTS IC<sub>50</sub> = 41.6 ± 1.9 µg/mL), stabilized erythrocyte membranes (IC<sub>50</sub> ≈ 14.8 µg/mL), and inhibited carbohydrate-hydrolyzing enzymes, with stronger inhibition of α-glucosidase (~92%) than α-amylase (~84%) at 128 µg/mL. <b>Conclusions:</b> Thymoquinone is a major bioactive constituent of <i>N. sativa</i> seeds, exhibiting consistent multi-target in vitro activity. These findings highlight its functional relevance and in vivo investigations to establish therapeutic potential.

Research topics

  • Nigella sativa pharmacological applications
  • Phytochemistry and Bioactivity Studies
  • Medical Research and Islamic Perspectives

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.3390/ph19030503

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.